Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable Discussion.

Autologous stem cell transplant (ASCT) is a standard-of-care treatment for patients with multiple myeloma (MM). However, only 20%-30% of patients with MM for whom the procedure is indicated undergo ASCT. Barriers to ASCT may be informational, financial, logistic, or cultural and may affect patients and/or treating oncologists. The availability and accessibility of accurate ASCT-related information are essential to overcome these barriers. Such resources can be created by blood and marrow transplantation societies and patient advocacy groups, ideally in collaboration with MM specialists at transplant centers. An umbrella office at the society level is also recommended to connect oncologists, advocacy groups, and transplant specialists; provide informational resources to patients; and conduct research into the region- and population-specific barriers to ASCT.